o2h discovery, a preclinical Contract Research Organization which has an integrated drug discovery platform, is pleased to announce the second edition of the o2h kickstarter competition exclusively aimed towards supporting Australian early stage biotech companies. After the overwhelming response to the first competition, we are back with another edition to specifically support early stage Aus Biotech in their drug discovery programmes.
Aus Biotech has a globally competitive biotech ecosystem which has impact significantly higher than its size compared to the overall global Biotech sector. We…
New company created to enable commercial manufacture of new cell and gene therapies
Cellular Origins’ proprietary technology will address current barriers associated with cost-effective and efficient manufacture of cell and gene therapies at scale
Cambridge, UK, 17 January 2023: TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary…
Expansion of five-year collaboration broadens established Organ-on-a-chip research demonstrating advanced performance of the PhysioMimix MPS
New research project to investigate the use of multi-organ MPS to improve estimation of human drug bioavailability in comparison to existing animal models
Cambridge, UK, 17th January 2023: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that the U.S. Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time,…
Howard Group appoints Hilson Moran as Sustainability Consultant for its flagship development Unity Campus
Cambridge, 16th January 2023: As part of its aspiration to achieve a net zero carbon property portfolio by 2035, Howard Group, the Cambridge-based property investor and developer, is pleased to announce the appointment of Hilson Moran as Sustainability Consultant for the Group’s flagship development Unity Campus. Hilson Moran has been commissioned to develop a sustainability strategy and implementation plan for…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA
License milestone to develop and commercialise ready-to-use medicine achieved
Arecor regains rights to AT282 following portfolio review at Hikma
Cambridge, UK, 12 January 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce a key advancement in the development of AT307, a ready-to-use (“RTU”) injectable medicine, with the transfer of development activities and achievement of the next license milestone…
Reddie & Grose, a UK and European firm of Patent, Trade Mark and Design attorneys, is delighted to announce that Dr Yumiko Kato has joined the firm as a Senior Associate. She will be working out of the London office.
Yumiko’s specialist field is chemistry where she holds particular experience in polymer chemistry, detergent compositions, printing ink compositions, material science, catalysis, nanotechnology and fluorocarbon chemistry. She also has extensive experience in pharmaceuticals and medical devices.
Having achieved a First Class Honours in MSci Chemistry from Imperial College…
Cambridge, UK, 10 Jan 2023: o2h technology, a business vertical of the o2h group, is excited to announce the launch of the o2h tech kickstarter competition exclusively for seed stage life science, greentech and tech/AI companies to help them boost their MVP, web, mobile app design & development activities.
o2h technology understands that it has always been a challenge for seed stage companies to design, build and scale their application/products due to various barriers including the high cost of hiring quality developers, access to CTO-level technology expertise, and access to expert…
Announcing The Herts Healthcare Accelerator programme at the University of Hertfordshire - designed to support the development of healthcare, biotech and medtech innovations, including new potential products, services, or allied technologies.
Successful applicants will access a tailored package of support worth around £13,500 per company from a range of industry and academic experts to help them deliver their proposed idea. For more information and to express interest follow the link below. The closing date for expressing an interest is 31st January.
https://www.herts.ac.uk/enterprise-zone/…
AMSBIO reports how the Faculty of Biological Sciences at the University of Leeds (UK) is using their specialty reagents for the production, visualization, and analysis of glycans and to investigate their interactions which are instrumental to the advance of glycobiology.
Glycobiology is vital for many biological processes — from fertilization to inflammation — helping unlock information about interactions between carbohydrates and proteins and providing the mechanism by which many viruses and bacteria latch on to healthy cells. Leading research groups around the world are using glycobiology…
Astrea Bioseparations (“Astrea Bio”), a leading provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd. ("Delta Precision"), a premier manufacturer of advanced chromatography columns for the biotechnology and pharmaceutical industries.
This strategic acquisition, which follows a long-standing relationship of almost a decade, will allow Astrea Bio to expand its product offering to include a full range of high-performance chromatography columns for biomanufacturing, complementing and strengthening the company's…